PER® Chemotherapy Foundation Symposium (CFS) | Conference

Navigating the Increasing Complexity of Therapeutic Sequencing for Relapsed/Refractory Multiple Myeloma

November 8th 2020

The treatment landscape of relapsed/ refractory multiple myeloma has undergone rapid changes over the past 2 decades, with over a dozen drug approvals by the FDA.

Need for Germline Testing Becomes Increasingly Pronounced in Oncology

November 6th 2020

Mark E. Robson, MD, discusses how a strong cognizance of germline testing is becoming increasingly important in the field of oncology, across an array of tumor types.

Dr. Markman on the Benefit of PARP Inhibitors in Ovarian Cancer

November 6th 2020

Maurie Markman, MD, discusses the utility of PARP inhibitors in ovarian cancer.

Dr. Yu on the Role of Radiation in Prostate Cancer

November 6th 2020

James B. Yu, MD, MHS, discusses the utility of radiation in men with prostate cancer.

NCI Director Talks Response to COVID-19 Crisis, Focuses on Overcoming Disruptions in Cancer Care

November 6th 2020

Norman E. “Ned” Sharpless, MD, discusses the efforts that The National Cancer Institute has made to combat the coronavirus disease 2019 pandemic.

Hudis Emphasizes Need for Cancer Research Funding During CFS® Keynote

November 6th 2020

Clifford A. Hudis, MD, CEO highlights cancer mortality and how it has steadily declined in the United States since 1975.

Unlocking the Potential of Targeted Treatment Options for HCC

November 6th 2020

Targeted agents have restructured the treatment paradigm for patients with advanced hepatocellular carcinoma. The present challenge is to identify the patients most likely to benefit from frontline treatment regimens.

Dr. Weber on the Evolution of Melanoma Treatment

November 5th 2020

Jeffrey S. Weber, MD, PhD, discusses the evolution of the treatment paradigm in melanoma.

Immunotherapy in Gynecologic Cancers Shows Progress but Has a Long Way to Go

November 5th 2020

Ursula Matulonis, MD, highlights immunotherapy agents have demonstrated moderate clinical activity for patients with gynecologic cancers, however they fail to yield significant response rates in both the newly-diagnosed and recurrent settings.

Dr. Jhaveri on Outlining First-Line Treatment in HER2+ Breast Cancer

November 5th 2020

Komal Jhaveri, MD, FACP, discusses the importance of outlining the first-line treatment course for patients with HER2-positive breast cancer.

The Art of Choosing Immunotherapy or BRAF-Targeted Treatment for Adjuvant Melanoma

November 5th 2020

There is still a great deal to learn about the optimal use of BRAF-targeted therapy, as well as immunotherapy, in the adjuvant setting for patients with melanoma.

Hussain Discusses Progress of PARP Inhibition in Metastatic Castration-Resistant Prostate Cancer

November 5th 2020

PARP inhibitors have emerged as a promising therapeutic target in prostate cancer at the 38th Annual CFS® virtual conference.

Novel Combinations Carry CDK4/6 Inhibitors Into the Future in HR+/HER2- Breast Cancer

November 5th 2020

Patients with advanced hormone receptor–positive, HER2-negative breast cancer still face acquired resistance, even with the most effective agents, namely CDK4/6 inhibitors, which have demonstrated unprecedented overall survival benefit in the metastatic setting.

Dr. Mascarenhas on the Promise of Imetelstat in Myelofibrosis

November 4th 2020

John O. Mascarenhas, MD, discusses the promise of imetelstat in myelofibrosis.

Dr. Pemmaraju on a New Era of Treatment Strategies in BPDCN

November 4th 2020

Naveen Pemmaraju, MD, discusses current treatment strategies in blastic plasmacytoid dendritic cell neoplasm.

Dr. Lonial on the Advantage of Targeting BCMA in Multiple Myeloma

November 4th 2020

Sagar Lonial, MD, FACP, discusses the advantage of targeting BCMA in multiple myeloma.

Mato Presents Sequencing Framework for Crowded CLL Landscape

November 4th 2020

An explosion of therapeutic options for chronic lymphocytic leukemia has resulted in challenging questions about sequencing therapies for patients who progress after frontline treatment with little data to guide optimal therapy selection.

Choosing the Optimal Frontline Approach for Low-Grade Follicular Lymphoma

November 4th 2020

Frontline treatment decisions for patients with follicular lymphoma can be guided by a general framework; the choice of therapy is often based on several factors such as indications of therapy, bulk of disease, comorbidities, and toxicity.

New Strategies Improve Outcomes for Lower-Risk MDS

November 4th 2020

Myelodysplastic syndrome is a challenging and complicated disease with median outcomes ranging from 5.3 years in patients with lower-risk disease to just 8.4 months in the very high-risk population.

BCMA-Targeting Drugs Take Center Stage in Myeloma

November 4th 2020

The treatment landscape for multiple myeloma is poised to enter a new era of innovation with the development of therapies that target B-cell maturation antigen, which is highly expressed on plasma and MM cells.